CHELMSFORD, Mass., March 10, 2020 /PRNewswire/ -- Brooks
Automation, Inc. (Nasdaq: BRKS), announced today new leadership
appointments and a realignment of its Life Sciences business
organization to enhance capabilities and provide for optimal growth
and efficiency.
Over the past decade, Brooks has undergone a transformation from
a pure semiconductor automation company to a company addressing two
distinct growth segments, with leadership positions in both the
Semiconductor equipment and the Life Sciences industries.
Over the years, the company has evolved its organization to support
the rapid growth of its businesses and to provide customer focused
leadership. As an important step in this transformation, in
September 2019, Steve Schwartz, president and CEO of Brooks,
assumed the interim role of the Life Sciences general manager with
deliberate intention to reshape the segment. Today, the
Company announced this transitional step has culminated in the
realignment of its operating units and the naming of new segment
leadership.
Since the acquisition of GENEWIZ in November 2018, Brooks Life Sciences has been
composed of two operating units, Sample Management and
GENEWIZ. The Company is realigning these operations
into the newly formed Life Sciences Services and Life Sciences
Products business units:
Life Sciences Services will combine GENEWIZ genomic
services with Biostorage sample management services under the
leadership of Dr. Amy Liao,
President of Life Sciences Services. Combining these two
service-based businesses will leverage the potential for synergies
as customers adopt outsourced services to manage a broad variety of
sample-based services including gene sequencing, gene synthesis,
lab analysis, sample kitting and preparation, transportation, and
storage. Dr. Liao, as the co-founder, former CEO and current
President of GENEWIZ, has been an industry insider for more than 20
years where she has accumulated substantial knowledge of the
researcher's challenges and the increasing value of the sample
assets.
Life Sciences Products will be composed of the sales and
delivery of all products, including the large automated ultra-cold
stores, automated cryogenic storage systems, and consumables and
instruments. This business unit will also include the
post-warranty service support of its products. Robin Vacha has been appointed Senior Vice
President and General Manager of Life Sciences Products. Mr.
Vacha has been with Brooks for more than five years leading global
semiconductor operations and has brought operational excellence to
the manufacturing and supply chain functions. He has
demonstrated deep commercial and customer insight as he has
partnered with our customers in the Semiconductor business.
Steve Schwartz, president and
CEO, commented on the new business alignment, "It is with great
resolve and confidence that we have made these new
appointments. Amy and Robin bring deep talents to their
respective businesses and are experienced in running a lean
operation to achieve high performance. Our customers will
benefit from the focus that each brings."
The realignment of the Life Sciences business units will be
effective April 1, 2020.
About Brooks Automation
Brooks is a leading
provider of life science and semiconductor manufacturing automation
solutions worldwide. The Company applies its automation and
cryogenics expertise to provide a full suite of reliable cold-chain
sample management solutions across life sciences in areas such as
drug development, clinical research and advanced cell
therapies. Brooks recently added global capability for gene
sequencing and gene synthesis services through its strategic
acquisition of GENEWIZ, expanding its sample-based services
offerings. With over 40 years as a partner to the
semiconductor manufacturing industry, Brooks is a provider of
industry-leading precision robotics, integrated automation systems
and services. Brooks is headquartered in Chelmsford, MA, with operations in
North America, Europe and Asia. For more information, visit
www.brooks.com.
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are
forward-looking statements made under Section 21E of the Securities
Exchange Act of 1934. These statements are neither promises nor
guarantees but involve risks and uncertainties, both known and
unknown, that could cause Brooks' financial and business results to
differ materially from our expectations. They are based on the
facts known to management at the time they are made. These
forward-looking statements include but are not limited to
statements about the future prospects of the Company's Life
Sciences segment and the benefits of the Company's realignment of
its Life Sciences segment and leadership appointments. Factors that
could cause results to differ from our expectations include the
following: the volatility of the industries the Company
serves, particularly the semiconductor industry; our possible
inability to meet demand for our products due to difficulties in
obtaining components and materials from our suppliers in required
quantities and of required quality; risks and uncertainties related
to the coronavirus originating in Wuhan,
China and its effects on the Company's operations in
China, including supply chain, and
the operations of our customers in China; the inability of customers to make
payments to us when due; the timing and effectiveness of cost
reduction and cost control measures; price competition; disputes
concerning intellectual property; uncertainties in global political
and economic conditions, and other factors and other risks,
including those that we have described in our filings with the
Securities and Exchange Commission, including but not limited to
our Annual Report on Form 10-K, current reports on Form 8-K and our
quarterly reports on Form 10-Q. As a result, we can provide no
assurance that our future results will not be materially different
from those projected. Brooks expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statement to reflect any change in our expectations or any
change in events, conditions or circumstances on which any such
statement is based. Brooks undertakes no obligation to update the
information contained in this press release.
INVESTOR CONTACTS:
Mark Namaroff
Director, Investor Relations
Brooks Automation
978.262.2635
mark.namaroff@brooks.com
Sherry Dinsmore
Brooks Automation
978.262.2400
sherry.dinsmore@brooks.com
John Mills
Senior Managing Director
ICR, LLC
646.277.1254
John.mills@icrinc.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/brooks-automation-announces-realignment-of-its-life-sciences-segment-301021091.html
SOURCE Brooks Automation